•

•

•

•

•

•

•

•

•

ON ON ONOFF OFF OFF

•

•

•

•

•

•

•

H2O

H2O

Met

abolit

e 1

Met

abolit

e 2

Met

abolit

e 3

Met

abolit

e 4

Met

abolit

e 5

Met

abolit

e 6

Met

abolit

e 7

Met

abolit

e 8

Met

abolit

e 9

Met

abolit

e 10

Met

abolit

e 11

Met

abolit

e 12

100%

0.01%

0.1%

1%

10%

Carbon sources

Tobramycin 40mg/l

Su

rviv

al

•

•

• >

125KUS Non-CF BE

Patients

2.4MGlobal Non-CF BE

Patients30K

US CF Patients

70KGlobal CF Patients

•

1. Eva Polverino, William Cacheris, Cara Spencer, Elisabeth Operschall, Anne E O’Donnell. Global burden of non-cystic fibrosis bronchiectasis: a simple epidemiological analysis. Poster 3983. Presented at ERS 2012.

35-45%of COPD costs due to

exacerbations

50%of exacerbations due to bacterial infections

$29 Billion2010 US Direct COPD healthcare spending

*Psuedomonas frequency estimates in literature range from 10%-35%, 20% chosen as midpoint

•

•

•

•

•

•

–

–

–

–

•

–

–

–

–

•–

–

–

–

–

•–

–

•–

–

–

•–

–

–

•

•

•

Number of PJI Inpatient Hospital Costs of PJI

•

•

•

•

✔

✔

✔

✔

✔

Time course Inoculum Ratio